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 Oculocutaneous albinism (OCA) is a heterogeneous
group of autosomal recessive disorders that often results in
the reduction or complete absence of melanin in the skin, hair,
and eyes. It is also associated with common developmental
abnormalities of the eye. At least 16 different genes have been
identified that, when mutated, result in different types of albi-
nism [1]. All forms of OCA are represented with photopho-
bia, strabismus, moderate to severe visual impairment, and
nystagmus.
Oculocutaneous albinism type 1 (OCA1; OMIM 203100),
results from mutations in the tyrosinase gene (TYR, 11q14-
q21; OMIM 606933). The clinical phenotype resembling
OCA1 is caused by the absence of (OCA1A) or residual cata-
lytic activity of (OCA1B) tyrosinase [2]. TYR with 5 exons
spanning more than 65 kb of DNA [3] encodes a 58 kDa gly-
coprotein of 529 amino acids [4].
Despite a large number of reported TYR mutations (Albi-
nism database), very little is known about the molecular basis
of OCA in Indian patients although the disease is quite preva-
lent in some of the geographical locations. In the Bankura dis-
trict of West Bengal, OCA is common among the Tili ethnic
group. We initially reported the presence of a TYR mutation
(R278X) among the Tili [5]. A subsequent study confirmed
the presence of the same mutation and reported two frame-
shift mutations in four affected families representing an eth-
nic group, which was termed “either Tili or Tamli” [6]. These
family samples were collected from the same region of India.
It is important to note that Tili and Tamli are two distinct eth-
nic groups and hence may not have the same genetic basis for
occurrence of OCA. Tamli, also known as Tamuli or Tambuli,
mostly live in the Burdwan and Hooghly districts of West
Bengal. The available literature regarding their origin suggests
that they are an offshoot of one of the trading castes [7]. How-
ever, Tili or Teli, is a community whose name derives from
the Sanskrit word talika or taila, referring to the oil extracted
from sesame and mustard. Risley [7] suggested that they must
have been recruited from a different class of Hindu society.
In contrast to the recent report [6] on “Tili or Tamli” our
study based on 188 Tili individuals suggested a lack of any
mutation other than R278X among Tili, the ethnic group which
represents about 12.56% of the Bankura population (0.4 mil-
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lion). Therefore, we argue that the genetic basis of the disease
in the population group should be investigated thoroughly so
that advice regarding genetic screening and subsequent coun-
seling is based on clearly established facts for the relevant
ethnic or population group. Here we report results of our in-
vestigation based on OCA affected families, carefully selected
by interviewing the local Tili population group and using ex-
periments designed to provide unequivocal answers. The mu-
tation occurred in the same haplotype background suggesting
a founder effect. Our data suggest that R278X is the major, if
not exclusive, mutation within the Tili ethnic group.
METHODS
 Fourteen OCA affected Tili families, consisting of a total of
161 individuals including 26 patients, were recruited for the
study. Approximately 10 ml of peripheral blood samples were
collected in EDTA, from 48 Tili individuals including 19 pa-
tients, 29 family members with the normal phenotype, and an
OCA-affected boy and his normal brother belonging to the
Tamli (also known as Tambuli) ethnic group, with their in-
formed consent. The study protocols adhered to the tenets of
the Declaration of Helsinki and was approved by the Institu-
tional Review Board. Apart from albinism, the diagnosis in-
volved ophthalmologic examinations including the testing of
abnormal ocular movement (nystagmus and strabismus), a
visual acuity test, fundoscopy, and tests for other ocular in-
volvement such as cataract, glaucoma, or retinal diseases.
Controls were selected from the general Tili population with-
out any family history of ocular disease or albinism to deter-
mine the frequency of the carriers for the TYR mutation. Prior
to collection of blood samples, a government-registered local
organization for the welfare of the Tili community was con-
tacted for information on the ethnic group. Next, one of us
(SS), a clinician working in the Bankura district for last 25
years and having good knowledge about the community, vis-
ited individual households of Tili families, interviewed house-
hold members to ensure their ethnicity along with other rel-
evant information regarding OCA, and collected the blood
samples with the consent of the donors.
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TABLE 1. PRIMERS AND PCR CONDITIONS FOR AMPLIFICATION OF TYR EXONS 1, 2, AND 3
                                         Amplified   Amplicon
    Primer    Primer sequence (5'-3')     region       (bp)          PCR condition
    ------   -------------------------   ---------   --------   ------------------------
Primers for SSCP
    Tyr1bF   GTTCCTGCAGACCTTGTGAGG       Exon 1         490     94 °C 30 s, 60 °C 30 s,
    Tyr1bR   GATGACATAGTCTGAGCTGATGG                            72 °C 30 s for 30 cycles
    Tyr1cF   CTTCATGGGATTCAACTGTGG       Exon 1         596     94 °C 30 s, 58 °C 30 s,
    Tyr1cR   GAAGTGATTGTTAAGGTTCCTCC                            72 °C 30 s for 30 cycles
    Tyr2bF   CTACTGACTCAGTGGTGGTGAC      Exon 2         346     94 °C 30 s, 60 °C 30 s,
    Tyr2aR   CTCCTAGGACTTTGGATAAGAG                             72 °C 30 s for 30 cycles
    Tyr3bF   GGGATAATCACATAGGTTTTCAGTC   Exon 3         268     94 °C 30 s, 64 °C 30 s,
    Tyr3aR   CCTCTATTTAAATCCAATGAGCACG                          72 °C 30 s for 30 cycles
Primers for sequencing
    Tyr1aF   GTGAGCTATCCTTAGGAGTTGTC     Exon 1 &      1539     94 °C 30 s, 62 °C 30 s,
    Tyr1cR   GAAGTGATTGTTAAGGTTCCTCC     flanking               72 °C 90 s for 30 cycles
                                         region
    Tyr2aF   GCCATTATCTTACAATTGCC        Exon 2 &       730     94 °C 30 s, 50 °C 30 s,
    Tyr2bR   TGAATTATAACGTGCTGACC        flanking               72 °C 1 min for 30 cycles
                                         region
    Tyr3aF   GGCTCAACCTCTTTTACCTGG       Exon 3 &       938     94 °C 30 s, 56 °C 30 s,
    Tyr3bR   CCTATAGCAGTTCTGTGTGTCC      flanking               72 °C 1 min for 30 cycles
                                         region
The 490 bp fragment amplicon of Tyr1bF and Tyr1bR was digested with the NlaIV (New England Biolabs, Beverly, MA) to generate 3 smaller
fragments (127 bp, 167 bp, and 192 bp) and subjected to SSCP. The 596 bp fragment amplicon of Tyr1cF and Tyr1cR was digested with the
XcmI (New England Biolabs, Beverly, MA) to generate 3 smaller fragments (168 bp, 197 bp, and 229 bp) and subjected to SSCP. The three
amplicons of TYR were sequenced using nested primers. For exon 1, Tyr1aR (CTCTAGGGAAATGGCCAGCGG), Tyr1bF, and Tyr1cF were
used. For exon 2, Tyr2bF and Tyr2aR were used. For exon 3, Tyr3bF and Tyr3aR were used. The PCR conditions used 2.0 mM MgCl2 except
for Tyr3aF and Tyr3bR which used using 1.5 mM MgCl2.
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A tyrosinase hair bulb assay was performed to identify
potential OCA1 cases [8]. The coding sequence and splice
site junctions of TYR were amplified from the genomic DNA
of the patients and controls, and the mutation was identified
by direct DNA sequencing of the samples showing band-shift
in SSCP. While exons 1-3 were amplified following standard
protocol (Table 1), exons 4 and 5 were amplified using gene
specific primers to avoid co-amplification of the pseudogene
TYRL (OMIM 191270) based on our recently described method
[9]. Three CA-repeat markers (GDB:11511689,
GDB:11511691, and GDB:11511690), identified within the
TYR locus and its flanking regions, were used to determine
the genotypes of the patients and their parents. Genescan analy-
sis was done in the ABI Prism 3100 DNA Sequencing System
using 500 ROX Size Standard (Applied Biosystems, Foster
City, CA). The mutation identified by DNA sequencing was
analyzed in the additional control Tili samples with BslI re-
striction enzyme (New England BioLabs, Beverly, MA). The
mutant allele was indicated by the loss of the BslI site.
RESULTS & DISCUSSION
 In our sample pool, all the patients seemed to be affected with
OCA1 due to mutations in the TYR, as indicated by the tyrosi-
nase hair bulb assay. On clinical examination, these patients
were found to have the pigment deficiency in the peripheral
retina along with other associated changes to the visual sys-
tem including decreased visual acuity (usually diminished to
as low as 6/60) secondary to foveal hypoplasia, photophobia,
iris transillumination, nystagmus, strabismus, and loss of bin-
ocular vision.
 SSCP analysis revealed that all the Tili patients had the
same characteristic band shift (Figure 1A) of the amplicon
containing the sequences for the second exon of TYR. The
DNA sequence analysis (Figure 1B) of multiple patient samples
revealed the same homozygous change (c.832C>T) that would
create a premature stop codon (Arg278stop) resulting in a trun-
cated and completely inactive enzyme lacking one potential
copper binding region (OCA1A). The mutation occurred in a
CpG context and reported previously in different population
groups, for example, Japanese [10], Guayanan [11], Morroccan
Jewish [12], and Indo-Pakistani [13] populations. To examine
whether the prevalence of this mutation in the Tili population
was due to a founder effect, we did haplotype analysis using
the newly identified microsatellite markers (GDB:11511689,
GDB:11511691, and GDB:11511690) within the TYR locus
and its flanking regions. All 19 patients were found to have
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Figure 1. Detection of Arg278stop mutation.  A: The location of the
mutation within TYR exon 2 is shown. A 12.5% SSCP gel shows
characteristic band shifts for the Tili patients (lanes 1, 3), obligate
carriers for the mutation (lanes 2, 4) and a normal individual (lane
5). B: A representative chromatogram is shown with the location of
the homozygous mutation c.832C>T (Arg278stop) indicated by an
arrow. C: The allelic difference resulting from the mutation was de-
termined by BslI digestion of the PCR product from exon 2 of the
gene. Polyacrylamide gel (6%) analysis of BslI digests from five
members of a pedigree and their genotypes are shown. The mutation
abolishes the BslI site. The marker lane contains pBS/HaeIII digested
DNA fragments. The sizes of the molecular weight marker and the
BslI digested DNA fragments are shown on the left and right sides of
the gel, respectively.    
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the same haplotype (179-101-157). The same result was ob-
tained using a set of SNP markers: 1-533G->C, 1-301C->T,
1-199C->A, c.575C->A (S192Y), c1037-201G->A(data not
shown).
To determine the carrier frequency of this mutation within
this ethnic group, an RFLP-based diagnostic assay was per-
formed (Figure 1C) on the DNA samples from 27 unrelated
normal individuals of the same population group, who on spe-
cific inquiry informed us that they did not have any OCA af-
fected members in their families. As a larger number of such
donors were difficult to obtain, based on the limited samples,
the initial carrier frequency of the mutation was found to be
11.11% (3/54 alleles) among the Tili and the disease frequency
was estimated to be significantly higher than the world aver-
age [14].
In a recent paper [6], in addition to R278X, two frame-
shift mutations have also been reported in exons 2 and 5, to
cause OCA in the “Tili or Tamli” ethnic groups of West Ben-
gal, India. To investigate the occurrence of these two muta-
tions in the Tili and Tamli populations (these are not the same
groups as mentioned earlier), we directly sequenced exons 2
and 5 from OCA patients of both these ethnic groups. We
amplified TYR exon 5 (avoiding co-amplification of the
pseudogene TYRL) as we recently described [9]. Our investi-
gation clearly showed that while the Tamli patient was a com-
pound heterozygote for Arg278stop and c.1379delTT (data not
shown), none of the Tili individuals (patients, their family
members, or unrelated controls) contained the deletion muta-
tion in exon 5 of TYR. We did not detect a deletion mutation in
Exon 2 of any individual of our cohort, consisting of 14 large
Tili families and one Tamli family. The R278X mutant chro-
mosome in the Tamli family has the same haplotype as in the
Tili mutation suggesting a common origin for both. It is likely
that the mutation was introduced into the Tamli lineage by the
marriage of a person of this community to a Tili individual
harboring the mutation. However, such marriages are relatively
uncommon.
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